BioSpectrum
the business of Bio & Health Sciences

Glenmark receives ANDA approval for generic version of Micardis® HCT Tablets

05 March 2019 | News | By Kalyani Sharma

Glenmark's current portfolio consists of 150 products authorized for distribution in the U.S. marketplace

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis®1 HCT Tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending January 2019, the Micardis® HCT Tablets market achieved annual sales of approximately $40.6 million.

Glenmark's current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA's pending approval with the U.S. FDA.